A phase III trial of setmelanotide in patients with pro-opiomelanocortin (POMC) deficiency obesity

Trial Profile

A phase III trial of setmelanotide in patients with pro-opiomelanocortin (POMC) deficiency obesity

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Jul 2018

At a glance

  • Drugs Setmelanotide (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Sponsors Rhythm
  • Most Recent Events

    • 23 Jul 2018 Status changed from recruiting to active, no longer recruiting, as reported in a Rhythm Pharmaceuticals media release.
    • 14 Jun 2018 According to a Rhythm Pharmaceuticals media release, the company expects to report initial data from this trial in the third quarter of 2019.
    • 14 Jun 2018 According to a Rhythm Pharmaceuticals media release, enrollment of the pivotal cohort of 10 patients has been completed in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top